Premna (Premna serratifolia L.): A Comprehensive Reference
1. Identity: Botanical Classification, Nomenclature, and Natural Source
1.1 Accepted Name and Synonymy
Premna serratifolia is a species of small tree or shrub in the family Lamiaceae. Its taxonomy has historically been unsettled, generating a substantial list of synonyms. Premna serratifolia L. carries the synonyms Premna integrifolia L. and Premna obtusifolia R. Br., and belongs to the family Verbenaceae as it was formerly classified — an essential ingredient of many important Ayurvedic drugs. According to the Royal Botanic Gardens, Kew's authoritative Plants of the World Online database, the name Premna integrifolia is now treated as a synonym of Premna serratifolia. The species was first formally described by Linnaeus in 1771, as reflected in the citation Premna serratifolia L., Mant. Pl. 2: 253.
The genus Premna was previously classified within the family Verbenaceae, but has since been transferred into the family Lamiaceae, subfamily Viticoideae. Currently the genus contains approximately 200 species mainly distributed throughout tropical and subtropical Asia, Africa, Australia, and the Pacific Islands. There are 46 species recognized in the Flora of China and 14 species occurring in the Flora Malesiana area.
The word 'Premna' is derived from the Greek 'premnon', meaning tree stump, which refers to the short and twisted trunks of P. serratifolia L., the first collected species of this genus.
1.2 Common and Vernacular Names
The species accumulates common names across its vast range. It is known as Agnimantha and Arani in Ayurveda and Indian traditional medicine. P. serratifolia is commonly known as the headache tree, piak, or arani. It is commonly known as Bruhat Agnimantha in Ayurvedic medicine. In the Philippines, it is also called Alagau-gubat or Mulawin-aso. In Tentena, Central Sulawesi, Indonesia, it is known as Arogo and is a popular vegetable.
1.3 Botanical Description and Natural Habitat
P. integrifolia is a scandent, erect shrub or small tree, more or less thorny on the trunk and large branches; it can be a large shrub or small tree up to 10 m tall, with a bole up to 30 cm in diameter, much-branched and sometimes spiny, bark fissured-flaky, brownish-grey, with branches that are spinous usually. Leaves are simple, opposite, estipulate; petiole 4–14 mm, slender, pubescent; lamina 2.5–8.5 × 2–7.2 cm, elliptic or elliptic-oblong; lateral nerves 3–5 pairs, pinnate, prominent. Fruits are drupes, black-coloured, obovoid–globose, 3–6 mm long, green turning black, pear-shaped; fruits appear in August–September.
It mostly grows in moist sandy soil and scrub jungles along seacoasts and mangrove forests. The native range of this species spans East Africa, the West Indian Ocean, and tropical and subtropical Asia to the Pacific; it grows primarily in the wet tropical biome.
1.4 Common Dosage Forms and Preparations
Multiple plant parts are used medicinally, including roots, root bark, stem bark, leaves, flowers, and fruits. Preparations documented in the scientific literature include:
- Decoctions (Kvatha): Roots and leaves boiled in water; roots of P. integrifolia are widely used for the preparation of Ayurvedic formulations such as Dashamoola-kvatha, Arishta, Churna, and Chyawanprash-avaleha.
- Methanol and ethanol extracts: Used extensively in pharmacological studies, typically prepared by macerating powdered dried material in the solvent of choice.
- Aqueous extracts (infusions and decoctions): Water extract of P. serratifolia leaves was prepared using 2 g of powdered dried leaves decocted in 200 mL of boiled deionized water, kept at 90°C to a final volume of 100 mL.
- Powders (Churna): Dried, ground plant material used in classical Ayurvedic formulations.
- Polyherbal formulations: In traditional medicines, P. integrifolia roots are an important ingredient of 'Dashmoolarishta,' which is well known for reconditioning the normal health of postpartum females.
2. Traditional and Historical Use
2.1 Ayurveda, Siddha, and Unani
Premna integrifolia Linn. is an important woody medicinal plant and has had a prominent place in the Ayurveda, Siddha, and Unani systems of medicines. Known in Ayurveda as Bruhat Agnimantha, it is a time-honored medicinal plant with long-standing use in treating ailments such as fever, inflammation, digestive troubles, and respiratory conditions.
In the Ayurvedic classics, Agnimantha is considered under the descriptions of Jaya-Dwaya by the Charaka Samhita and Ashtanga Hridaya. Two drugs — Agnimantha and Tarkari — were quoted simultaneously in several contexts. The Amarakosha dealt with these two drugs separately, listing synonyms such as Jaya, Jayanti, Nadeya, and Vyjayantika for Tarkari, and Shriparni, Agnimantha, Karnika, and Ganikarika for Agnimantha.
P. integrifolia is an integral component of several classical Ayurvedic formulations such as Dashamoola. The Dashamoola ("ten roots") is one of Ayurveda's most celebrated compound formulations, and P. integrifolia is an important constituent of the formulation of ten roots of herbs known as Dashamula and is widely used for treating various ailments in the Indian system of medicine.
The root of P. integrifolia is broadly utilized in the manufacture of Ayurvedic pharmaceutical products, such as Dasamula Kvatha and Chayawanprash Avaleha. Its formulation is used in treating various diseases such as inflammation, allergy, cough and cold, bronchitis, asthma, pain, wound healing, diabetes, and arthritis.
2.2 Traditional Uses by Plant Part
Traditional uses documented across ethnobotanical literature span the entire plant:
- Roots: Roots have various medicinal properties and have been used for the treatment of diabetes, chyluria, inflammation, swelling, headache, bronchitis, liver complications, and fever.
- Stem bark: Stem bark is used as an anti-malarial; the alkali extracted from the ash of the bark is used in ascites.
- Wood: In the indigenous system of medicine, wood of P. serratifolia is reported to be useful in the treatment of arthritis.
- Leaves: Extract of leaves has been used for cleaning wounds and for treating ticks and fleas; leaves are applied over the bladder to facilitate urination; leaves are applied externally to piles and tumours, and decoctions are given for flatulence.
- Flowers and whole plant: Flowers are used for rheumatism, neuralgia, cold, and fever; the whole plant is used in the form of decoction in rheumatism and neuralgia.
2.3 Geographic Spread of Traditional Use
The earliest documented report was on ethnomedicinal values of ten species of Premna throughout East and Southeast Asia, notably to treat malaria, stomach disorders, headache, cough, and tuberculosis. Unlike other species which are endemic in certain regions, P. serratifolia is widely distributed throughout the habitat region, which explains its popularity in traditional medicine to treat various diseases; in tropical Asia and East Africa, this species is notably used to treat neuralgia and headache, stomach ailments, fevers, colds and cough, and also to improve liver and cardiac-related problems.
The leaves of P. serratifolia are commonly consumed as a food ingredient in Tentena, Central Sulawesi, Indonesia. Different parts of P. serratifolia, including fruit, roots, barks, and leaves, have been used in folk medicine for the treatment of a number of illnesses, such as stomach disorders, diabetes, cough, rheumatism, inflammatory, and cardiovascular disorders.
It is widely used by traditional practitioners as a cardiotonic, antibiotic, anti-coagulant, stomachic, carminative, hepatoprotective, and antitumor agent.
3. Key Chemical Constituents and Active Compounds
3.1 Overall Phytochemical Profile
More than 250 compounds have been isolated and identified from Premna species, comprising diterpenoids, iridoid glycosides, and flavonoids as the most common secondary metabolites, followed by sesquiterpenes, lignans, phenylethanoids, megastigmanes, glyceroglycolipids, and ceramides.
The plant is rich in a diverse array of bioactive compounds, including alkaloids, flavonoids, tannins, phenolic acids, saponins, and essential oils, which contribute to its wide spectrum of biological activities.
3.2 Major Compound Classes
Iridoid Glycosides: Phytochemical investigations have revealed the presence of several glycosides including iridoid glycosides and phenylethanoids like premnethanoside A and B, some xanthones, steroids and saponins, flavonoids, triterpenoids, and diterpenoids (including premnones A and C) in Premna serratifolia leaves. From the stem bark specifically, iridoid glycosides — namely premnadimer, 4-hydroxyasarinin-1-O-glucopyranoside, 10-O-trans-p-coumaroylcatalpol, 4-hydroxy-E-globularinin, premnosidic acid, and 10-O-trans-p-coumaroyl-6-O-l-rhamnopyranosyl catalpol — have been isolated and evaluated for their radical-scavenging activity.
Phenylethanoid Glycoside — Acteoside (Verbacoside): Antioxidant activity was routinely monitored using the DPPH radical-scavenging assay while phytochemical investigation was based on HPLC analysis; through comprehensive spectroscopy studies, the isolated active antioxidant principle was identified as acteoside (verbacoside). Quantitatively, acteoside was found to be about four times more active (IC50 18.3 ± 3.7 µg/mL; 11.4 ± 2.3 µM) than the crude root wood extract (73.8 ± 2.4 µg/mL), and could account for most of the reported pharmacological activity of P. serratifolia.
Diterpenoids: The root bark of the plant has been shown to contain a potent cytotoxic and antioxidant diterpene, 11,12,16-trihydroxy-2-oxo-5-methyl-10-demethyl-abieta-1[10],6,8,11,13-pentene. Three additional diterpenoids — 1β,3α,8β-trihydroxy-pimara-15-ene, 6α,11,12,16-tetrahydroxy-7-oxo-abieta-8,11,13-triene, and 2α,19-dihydroxy-pimara-7,15-diene — have been reported, along with p-methoxy cinnamic acid, linalool, linoleic acid, β-sitosterol, and flavone luteolin, iridoid glycoside, premnine, ganiarine, ganikarine, premnazole, aphelandrine, pentacyclic terpene betulin, caryophellene, premnenol, and premnaspirodiene.
Furofuran Lignans: From the stem bark, premnadimer and 4-hydroxyasarinin-1-O-glucopyranoside, along with 9 known compounds, were identified as furofuran lignans. Furofuran lignans and iridoid glycosides might contribute to antioxidant activity of the stem bark of P. integrifolia when evaluated with radical-scavenging (DPPH and NO) and ferric-reducing antioxidant power (FRAP) assays.
Flavonoids: Secondary metabolites such as flavonoids, xanthones, chalcone, and other phenolic compounds with high hydroxyl-group substitution are hypothetically contributing to the high antioxidant activity of the plant. Luteolin has been specifically confirmed in leaves. Two flavone glycosides from P. latifolia leaves significantly inhibited oxidation of DPPH (IC50 22.5 and 16.0 µg/mL, respectively).
Polyphenolic Compounds (UPLC-MS confirmed): UPLC-Q-TOF-MS/MS analysis confirmed the presence of 12 polyphenolic compounds in root aqueous extract, namely 4-hydroxy-3-methoxycinnamic acid, linarin, peonidin-3,5-O-di-beta-glucopyranoside, diosmin, trans-cinnamic acid, daidzein, saponarin, homoorietin, acacetin, sarsasapogenin, phytol, and sissotrin.
4. Mechanisms of Action
4.1 Anti-Inflammatory Pathways
The most thoroughly investigated mechanistic pathway is inhibition of inflammatory mediator enzymes. In a study evaluating anti-inflammatory and immunomodulatory properties of P. integrifolia root extracts employing COX-1, COX-2, and 5-LOX enzyme-based assays, petroleum ether extract (PEE) showed potent inhibition of COX-2 and 5-LOX with IC50 values of 6.15 µg/mL and 11.33 µg/mL, respectively.
In in vitro studies on RAW 264.7 cell line, PEE showed inhibition in the formation of nitric oxide (NO), pro-inflammatory cytokines (IL-1β, IL-6), prostaglandin E2 (PGE2) production, induction of anti-inflammatory cytokine (IL-2), and down-regulation of expression of COX-2, 5-LOX, TNF-α, IL-1β, and iNOS. Further isolation by RP-HPLC resulted in the identification of four active peaks inhibiting COX-1, COX-2, and 5-LOX, out of which H3 was identified as 6-hydroxysalvinolone (6-HS). The present work demonstrated that spirostanol glycoside and furostanol glycoside were identified as two novel classes of dual inhibitors of 5-LOX/COX-2 enzymes; these natural products represent a novel class of anti-inflammatory agents with the potential for improved efficacy and reduced side effects.
The anti-inflammatory activity of P. integrifolia roots in various experimental models operates probably through antihistaminic, antikinin, COX-inhibitory, and antioxidant actions, which justifies the folkloric use of the plant.
4.2 Antioxidant Mechanisms
Various methods have been used to measure the antioxidant capacities, including radical scavenging (DPPH, superoxide, nitric oxide, hydroxyl radicals), ferric reducing ability of plasma (FRAP), ferric thiocyanate (FTC), lipid peroxidation, erythrocyte membrane stabilization, and β-carotene bleaching assays. The identification of acteoside (verbacoside) as the principal antioxidant molecule in root wood is the best-characterized specific mechanism: the molecule's catechol moiety enables potent electron donation and free-radical capture at markedly lower concentrations than crude extracts.
4.3 Neuropharmacological Mechanisms
At doses of 400 and 500 mg/kg orally, P. integrifolia extract decreased locomotor activity and moderately increased sleeping time, effects comparable to those of the CNS depressant chlorpromazine (10 mg/kg, i.p.), yet significantly different from those of the CNS stimulant ephedrine hydrochloride (10 mg/kg, i.p.). A study also evaluated the effect of P. integrifolia bark on locomotor activity in rats using open-field and hole-cross tests; the findings suggested that P. integrifolia significantly affected locomotor activity at doses of 250 and 500 mg/kg orally, and therefore might act as a CNS depressant.
5. Scientific Evidence by Area of Use
Note: The great majority of pharmacological studies on Premna are preclinical, conducted in animal models or in vitro. No controlled clinical trials in humans were located in the peer-reviewed literature as of the time of this review. All claims of efficacy in this section refer to animal and in vitro evidence unless specifically stated otherwise.
5.1 Anti-Inflammatory and Anti-Arthritic Activity
Evidence strength: Moderate (animal and in vitro; no human trials identified).
Pre-treatment with a single dose of methanolic extract of P. integrifolia (PIM) at 300 mg/kg body weight produced significant inhibition of carrageenan-induced rat hind paw edema, histamine-induced wheal formation, and acetic acid-induced mouse vascular permeation; in a 7-day study, daily administration of PIM suppressed formalin-induced paw edema and cotton pellet-induced rat granuloma formation. The extract also showed significant inhibition of cyclooxygenase (COX-I) activity on rat uterus and plasma membrane stabilization.
A separate study on bark extract confirmed these findings at different doses: at 200 mg/kg body weight dose, methanolic extract of P. integrifolia bark (MEPI) showed 71.16% inhibition in carrageenan-induced anti-inflammatory activity.
For arthritis specifically, anti-arthritic activity of ethanol extract of Premna serratifolia wood was evaluated using Freund's adjuvant-induced arthritis model in an animal study. In the Ayurvedic system of medicine, this plant has been used in the treatment of rheumatoid arthritis. The traditional use is thus supported by animal model data, but no human clinical trials have been conducted.
5.2 Antioxidant Activity
Evidence strength: Moderate (multiple in vitro assay systems; no human trials identified).
Several pharmacological activities including antioxidant effects and phytochemical investigations have been previously reported for the various parts of the plant, with particular focus on root woody tissues. The identification of acteoside as the specific active principle, with an IC50 approximately four times better than the crude extract, provides a chemically characterized mechanistic basis for the activity. Significant scavenging activity was observed in DPPH and NO assays using isolated iridoid glycosides from the stem bark. Research has investigated the antioxidant activity of ethanol and water extracts of P. serratifolia leaves based on their scavenging activities on DPPH radicals and their reducing capacities, including CuPRAC, total antioxidant/phosphomolybdenum, and ferric thiocyanate reducing power assays.
5.3 Antimicrobial Activity
Evidence strength: Preliminary (in vitro; no human trials identified).
Many studies have been carried out to evaluate the antibacterial and antifungal activities of extracts of Premna species; several studies have identified active antimicrobial compounds, mostly found as diterpenes. Earlier work successfully isolated an orange crystal substance from the alcoholic extract of the root bark of P. integrifolia that was active against Micrococcus aureus, Bacillus subtilis, and Streptococcus haemolyticus (MIC 0–25 µg/mL) but inactive towards Escherichia coli, Salmonella typhosa, and B. dysentriae. These findings are preliminary and confined to in vitro systems.
5.4 Hepatoprotective Activity
Evidence strength: Preliminary (animal models; no human trials identified).
Multiple animal-based studies have evaluated hepatoprotective potential. A study evaluated the hepatoprotective role of ethanol extract of P. integrifolia leaves on aflatoxin B1-induced toxicity in mice, in which mice were administered aflatoxin B1 (0.1 mg/kg body weight, orally) for 90 days, with EEPL at 400 and 600 mg/kg body weight orally. A separate study demonstrated hepatoprotection against cyclophosphamide-induced toxicity. Various in vivo and in vitro studies have shown cardioprotective, anti-inflammatory, immunomodulatory, anti-arthritic, anti-diabetic, anti-cancer, and hepatoprotective effects of P. integrifolia. The mechanisms appear to involve modulation of oxidative stress and apoptosis pathways.
5.5 Antidiabetic / Enzyme Inhibition Activity
Evidence strength: Preliminary (in vitro and animal models; no human trials identified).
Inhibition potentials of P. serratifolia extracts against several enzymes related to metabolic diseases — including α-glucosidase, α-amylase, xanthine oxidase, and protease — have been evaluated. Study findings suggested that methanolic extract of P. integrifolia provides scientific support for the use of this species in traditional medicine for diabetes mellitus. These results remain at the level of enzymatic and animal studies.
5.6 Cytotoxic / Anticancer Activity
Evidence strength: Preliminary (in vitro cell lines only; no human trials identified).
Preliminary cytotoxic activity of the P. serratifolia leaf methanol extract has been evaluated against liver (HepG2), lung (A549), and breast (MCF7) cancer cell lines by MTT assay; alcoholic extract of leaves also exhibited significant in vitro cytotoxic activity against Ehrlich ascites carcinoma cell lines.
An aqueous root extract study found that the cytotoxic potential of aqueous extract of root of P. serratifolia against human hepatoblastoma cancer cell line (HepG2) exhibits an IC50 value of 1000 µg/mL after 48 hours of incubation, suggesting relatively modest activity at high concentrations in this particular assay. Hoechst and AO/EtBr staining, ROS measurement, mitochondrial membrane potential, clonogenic, and wound healing assays confirmed the cytotoxic efficacy in a dose- and time-dependent manner.
For isolated constituents, isolates from the n-hexane soluble fraction of P. serratifolia leaf were tested on cancer cell lines MCF-7 and HT-29 for cytotoxicity; one compound showed significant cytotoxicity, leading to the conclusion that plant isolates showed cytotoxicity against selected human cancer cell lines. All these findings are in vitro and have not been extended to clinical research.
5.7 Neuropharmacological (CNS Depressant / Analgesic) Activity
Evidence strength: Preliminary (rodent models; no human trials identified).
A statistically significant decrease in locomotor activity was observed at all doses in open-field and hole-cross tests; the extract significantly and dose-dependently reduced the writhing reflex in the acetic acid-induced writhing test and licking response in formalin-induced inflammatory pain. The bark extract at 200 mg/kg showed clear CNS depressant characteristics comparable to reference drugs in rodent tests, but the clinical relevance of these findings has not been established.
5.8 Cardioprotective Activity
Evidence strength: Preliminary (animal and in vitro; no human trials identified).
Indigenous knowledge on P. serratifolia regarding its cardiotonic property is suggestive of certain novel cardiac principles; a foremost effort to identify a cardiac glycoside principle in its roots was undertaken by HPTLC using Digitalis purpurea and digoxin as positive standards. Detection of a compound similar to digoxin in the roots of P. serratifolia justifies its indigenous medicinal property as a cardiotonic drug. Further studies are needed to confirm the structural identity of this newly reported cardiac principle.
5.9 Overall Assessment of the Evidence Base
Adequate biological and pharmacological studies on most species in the genus Premna have not yet been performed, because most, especially in vivo studies, were carried out using crude extracts. For example, none of the bioactive molecules have been definitively identified from the active antimalarial Premna species. Similarly, some Premna species showed potential in vivo antihyperlipidemic, cardioprotective, hepatoprotective, gastroprotective, and neuropharmacological activities that require further studies to determine the active compounds and possible mechanisms. There is a need to validate traditional uses, isolate and confirm reported phytoconstituents, and determine biological and clinical efficacy by modern analytical and biological techniques.
6. Body Systems and Health Areas Associated With Premna
Based on the totality of the ethnobotanical and preclinical evidence, Premna species are associated with the following body systems:
- Musculoskeletal system: Anti-arthritic and anti-rheumatic use, with preclinical evidence in adjuvant-induced arthritis models.
- Immune system: Pharmacological studies conducted so far confirm the ethnomedicinal uses of P. serratifolia including antioxidant, antiarthritic, antiparasitic, and cardio- and gastroprotective activities.
- Hepatic system: Hepatoprotective activity demonstrated in multiple animal toxicity models, consistent with traditional use for liver complaints.
- Cardiovascular system: Traditional cardiotonic use and preliminary identification of digoxin-like cardiac principle in roots.
- Metabolic / Endocrine system: Antidiabetic enzyme inhibition activity (α-glucosidase and α-amylase) investigated in vitro and in animal models.
- Nervous system: CNS depressant and analgesic activities observed in rodent models; traditional use for headache, neuralgia.
- Respiratory system: Long-standing traditional use in treating fever, inflammation, digestive troubles, and respiratory conditions.
- Gastrointestinal system: Traditional use as a stomachic, carminative, and anti-flatulence agent; traditional use also for antiulcer activity.
7. Dosage Forms and Dosages Reported in Studies
The following dosages are taken directly from the primary scientific literature reviewed and refer exclusively to study-reported experimental doses, not clinical recommendations:
- Anti-inflammatory (rat/mouse, oral): Methanolic extract of P. integrifolia (PIM) at 300 mg/kg body weight was used as a single dose in acute inflammatory models.
- Anti-inflammatory (rat, oral, bark): At 200 mg/kg body weight, MEPI showed 71.16% inhibition in carrageenan-induced anti-inflammatory activity.
- Neuropharmacological (rat, oral): Doses of 400 and 500 mg/kg orally were used to assess CNS depressant activity. 250 and 500 mg/kg orally were used in open-field and hole-cross tests.
- Acute toxicity (mice, oral): In acute toxicity studies, single different doses (300–5000 mg/kg body weight) of ethyl acetate leaf extract did not produce any mortality in mice.
- Anti-arthritic (ethanol extract of wood, rodent, oral): In acute toxicity studies, the ethanol extract of P. serratifolia wood did not produce any toxic symptoms or mortality up to the dose level of 2000 mg/kg body weight in rats.
- Hepatoprotective (mice, oral): EEPL at 400 and 600 mg/kg body weight was administered orally alongside AFB1-induced hepatotoxicity in a 90-day murine study.
- Cytotoxic (in vitro): Aqueous root extract exhibited an IC50 value of 1000 µg/mL against HepG2 cells after 48 hours of incubation.
- COX-2/5-LOX inhibition (in vitro): Petroleum ether extract of P. integrifolia showed potent inhibition of COX-2 and 5-LOX with IC50 values of 6.15 µg/mL and 11.33 µg/mL, respectively.
No standardized oral human dosage has been established through clinical trials. Classical Ayurvedic texts specify dosages within the context of polyherbal formulations such as Dashamoola decoctions, but quantification of the P. integrifolia-specific dose within these preparations was not available in the peer-reviewed sources reviewed.
8. Safety Considerations
8.1 Animal Toxicity Studies
Acute and subacute toxicity studies of aqueous leaf extract of P. integrifolia provided a comprehensive evaluation of its safety profile; both studies demonstrated no mortality and only minor alterations in relative organ weights, hematology, and serum biochemistry, suggesting a low toxicity profile; additionally, the normal histoarchitecture of vital organs indicates the absence of significant morphological changes.
In acute toxicity studies it was observed that single different doses (300–5000 mg/kg body weight) of ethyl acetate leaf extract did not show any mortality in mice. Similarly, PIM (300 mg/kg body weight) produced no observable subacute toxicity in mice within 15 days.
8.2 Limitations in Safety Data
In general perception, herbal drugs are regarded as safe and without side effects; however, there is no sufficient evidence regarding the toxicity of these products to consumers. The limitation of plant-based herbal formulations is an unknown chemical composition and biological activity; its constituents may be beneficial or harmful to consumers. There is an urgent need to evaluate the safety and efficacy of these extracts for safe pharmaceutical applications, and without confirmation of safety, use in therapy is highly risky.
8.3 Cardiac Glycoside Content
A safety consideration particular to Premna is the detection of a digoxin-like compound in roots. Indigenous knowledge on P. serratifolia regarding its cardiotonic property is suggestive of certain novel cardiac principles; HPTLC identification of a compound similar to digoxin in the roots of P. serratifolia justifies its indigenous medicinal property as an effective cardiotonic drug. The presence of cardiac glycoside-like activity implies a need for caution in patients with cardiac conditions and in those taking prescribed cardiac drugs; however, the structural identity and pharmacokinetics of this compound have not been formally established.
8.4 Drug Interactions (Mechanistic/Preclinical Basis)
Based on the confirmed in vitro inhibition of COX-1, COX-2, and 5-LOX, concomitant use with nonsteroidal anti-inflammatory drugs (NSAIDs) or antiplatelet agents is theoretically relevant, as overlapping mechanisms could potentiate anti-inflammatory or anticoagulant effects. The traditional designation as "anti-coagulant" by practitioners further suggests caution with anticoagulant medications, though no pharmacokinetic or pharmacodynamic human interaction studies were found in the reviewed literature. Given the observed CNS depressant properties in animal models, caution alongside central nervous system depressant medications is also mechanistically indicated, though no human data exist to quantify this risk.
8.5 Taxonomic and Formulation Concerns
P. integrifolia is taxonomically ambiguous because of the wide variation in specimens obtained from various geographic locations, which introduces uncertainty about the consistency of phytochemical composition across commercial preparations. There is an inherent difference within the three Ayurvedic Formulary of India (AFIs) published with regard to the botanical sources of Agnimantha, meaning that preparations labeled "Agnimantha" in commerce may not uniformly contain P. serratifolia/integrifolia.
References
Go back